iPSC– tag –
-
Cynata Therapeutics to Announce Phase 3 iPSC-Derived MSC Results for Knee Osteoarthritis in June; Acute GVHD Phase 2 Nears Completion
Regen Report Australia Overview Cynata Therapeutics is set to release top-line results from its Phase 3 clinical trial, 'STOP-OA,' for knee osteoarthritis (KOA) using iPSC-derived mesenchymal stem cells (iPSC-MSC). The KOA trial database... -
Century Therapeutics to Present iPSC-Derived CNTY-813 (Featuring Allo-Evasion™ 5.0) for Type 1 Diabetes at ADA 86th Scientific Sessions
Benzinga USA Overview Century Therapeutics is scheduled to deliver an oral presentation on its innovative iPSC-derived islet cell replacement therapy, CNTY-813, for Type 1 diabetes at the American Diabetes Association (ADA) 86th Scientif... -
REPROCELL Unveils AI-Designed CRISPR for Hypoimmune iPSC Engineering, Accelerating Off-the-Shelf Cell Therapy Development
REPROCELL Japan Overview REPROCELL announced that its StemEdit platform, integrating AI-designed CRISPR with optimized workflows, has achieved high gene-editing efficiency and reduced off-target activity in induced pluripotent stem cells... -
Fate Therapeutics’ iPSC-Derived CAR T Therapy FT836 Shows Tumor Reduction and Favorable Safety Profile in KRASwt Colorectal Cancer Phase 1 Data at ASCO
GlobeNewswire (Fate Therapeutics Press Release) USA Overview Fate Therapeutics presented preliminary Phase 1 clinical data for its iPSC-derived, off-the-shelf CAR T-cell therapy, FT836, at the 2026 American Society of Clinical Oncology (... -
Japan: AMCHEPRY® for Parkinson’s (~$350,600) and RiHEART® for Severe Heart Failure (~$63,500+) iPSC Cell Therapies Show Positive Early Clinical Results in 7 Patients
Reddit (r/stemcells) Japan Overview Early clinical trials for Japan-originated iPSC cell therapies, AMCHEPRY® for Parkinson's disease and RiHEART® for severe ischemic heart failure, have shown positive results in a total of seven patient... -
Cynata Therapeutics Anticipates Announcing iPSC-MSC Clinical Results for Knee Osteoarthritis Phase 3 and Acute GvHD Phase 2 Trials Soon
Regen Report Australia Overview Australian cell therapy company Cynata Therapeutics has announced it will release results from two pivotal clinical trials using its iPSC-derived mesenchymal stem cells (iPSC-MSC) within months. These incl... -
Sana Biotechnology Reports 14-Month Positive Clinical Results for Immunosuppression-Free iPSC-Derived Islet Cell Transplant in Type 1 Diabetes
Simply Wall St (via Nasdaq:SANA) USA Overview Sana Biotechnology announced continued positive clinical results from its study of iPSC-derived islet cell transplantation (UP421) for Type 1 diabetes, spanning 14 months without immunosuppre... -
FUJIFILM Cellular Dynamics Quadruples iPSC Manufacturing Capacity with $200M New Facility in Wisconsin, Meeting Soaring Cell Therapy Demand
Manufacturing Dive USA Overview FUJIFILM Cellular Dynamics (FCDI) has inaugurated a new headquarters and iPSC development and manufacturing facility in Madison, Wisconsin, backed by a $200 million investment. This 170,000 square-foot exp... -
iPSC-Derived Retinal Sheet Transplantation for Retinitis Pigmentosa: Clinical Trial Validates Long-Term Safety and Engraftment
臨床研究等提出・公開システム (jRCT) Japan Overview A pioneering clinical study (jRCTa050200027) conducted by Kobe City Eye Center Hospital has concluded, affirming the long-term safety and engraftment of allogeneic iPSC-derived retinal s... -
iPSC-Derived Cell Therapy Pipeline 2026: From Disease Modeling to Expanding Clinical Applications
BioInformant USA Overview As of 2026, the iPSC-derived cell therapy pipeline shows rapid advancements in disease modeling and drug discovery, though broad clinical use in human patients still faces challenges. iPSC-derived cells hold imm...
